KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Cost of Revenue (2021 - 2025)

Vir Biotechnology's Cost of Revenue history spans 5 years, with the latest figure at $11000.0 for Q2 2025.

  • For Q2 2025, Cost of Revenue fell 78.85% year-over-year to $11000.0; the TTM value through Jun 2025 reached $745000.0, down 21.33%, while the annual FY2025 figure was $26000.0, 96.92% down from the prior year.
  • Cost of Revenue for Q2 2025 was $11000.0 at Vir Biotechnology, down from $684000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $90.1 million in Q1 2022 and bottomed at $11000.0 in Q2 2025.
  • The 5-year median for Cost of Revenue is $971000.0 (2021), against an average of $13.5 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 2340.65% in 2022 before it crashed 99.92% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $56.9 million in 2021, then crashed by 89.46% to $6.0 million in 2022, then plummeted by 86.69% to $798000.0 in 2023, then dropped by 14.29% to $684000.0 in 2024, then tumbled by 98.39% to $11000.0 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Cost of Revenue are $11000.0 (Q2 2025), $684000.0 (Q4 2024), and $50000.0 (Q3 2024).